
We are pleased to share this article out today in @CD_AACR on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound mutations 🔥Fills an important unmet need for pts with ALK+ lung cancer and other solid tumors 📢Tune in for updated prelim efficacy&safety data from the global ongoing phase I/II study (ALKOVE-1) of NVL-655 to be presented TOMORROW at #ESMO2024! @ALKPositiveinc @ALKpositiveINT @MGHCancerCenter @MassGeneralNews @alexdrilon @MSKCancerCenter @BenjaminBesseMD @MLJohnsonMD2 @DRCamidge @jii_bum_lee @ViolaWZhu aacrjournals.org/cancerdisco…
































